Literature DB >> 9170894

Zinc lozenges reduce the duration of common cold symptoms.

.   

Abstract

A randomized, double-blind, placebo-controlled clinical trial has shown that treatment of the common cold with zinc gluconate lozenges resulted in a significant reduction in duration of symptoms of the cold. Patients received zinc-containing lozenges or placebo lozenges every 2 hours for the duration of cold symptoms. The median time to complete resolution of cold symptoms was 4.4 days in the zinc group compared with 7.6 days in the placebo group. The mechanism of action of zinc in treating the common cold remains unknown.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9170894      PMCID： PMC7110332          DOI： 10.1111/j.1753-4887.1997.tb01601.x

Source DB:  PubMed          Journal:  Nutr Rev        ISSN： 0029-6643            Impact factor:   7.110


  13 in total

1.  Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds.

Authors:  B M Farr; E M Conner; R F Betts; J Oleske; A Minnefor; J M Gwaltney
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

2.  Zinc gluconate lozenges for common cold. A double-blind clinical trial.

Authors:  K Weismann; J P Jakobsen; J E Weismann; U M Hammer; S M Nyholm; B Hansen; K E Lomholt; K Schmidt
Journal:  Dan Med Bull       Date:  1990-06

3.  Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance.

Authors:  G M Hill; G J Brewer; J E Juni; A S Prasad; R D Dick
Journal:  Am J Med Sci       Date:  1986-12       Impact factor: 2.378

4.  Stability constants of zinc complexes affect common cold treatment results.

Authors:  G A Eby
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  Zinc for the common cold.

Authors:  J C Godfrey
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

6.  Failure of effervescent zinc acetate lozenges to alter the course of upper respiratory tract infections in Australian adults.

Authors:  R M Douglas; H B Miles; B W Moore; P Ryan; C B Pinnock
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

7.  Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study.

Authors:  G A Eby; D R Davis; W W Halcomb
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

8.  Zinc(II) in saliva: determination of concentrations produced by different formulations of zinc gluconate lozenges containing common excipients.

Authors:  J E Zarembo; J C Godfrey; N J Godfrey
Journal:  J Pharm Sci       Date:  1992-02       Impact factor: 3.534

9.  Zinc gluconate and the common cold: a controlled clinical study.

Authors:  J C Godfrey; B Conant Sloane; D S Smith; J H Turco; N Mercer; N J Godfrey
Journal:  J Int Med Res       Date:  1992-06       Impact factor: 1.671

10.  Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges.

Authors:  W Al-Nakib; P G Higgins; I Barrow; G Batstone; D A Tyrrell
Journal:  J Antimicrob Chemother       Date:  1987-12       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.